Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02832037 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 509
- Enrollment target
NCT02832037: Completed Phase 2 study, sponsored by Boehringer Ingelheim.
NCT02832037 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 509 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02832037, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 509 participants
- Enrollment target
Study Summary
The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.
Primary Outcome
MCCB overall composite T-score was derived from scores of 7 cognitive domains (Speed of Processing, Verbal Learning, Working Memory, Reasoning and Problem Solving, Visual Learning, Social Cognition, Attention) obtained from a total of 10 tests (Trail Making, Brief Assessment of Cognition in Schizophrenia, Hopkins Verbal Learning, Wechsler Memory Scale, Letter-Number Span, Neuropsychological Assessment Battery, Brief Visuospatial Memory, Category Fluency, Mayer-Salovey-Caruso Emotional Intelligen
Interventions
- DRUG Placebo
- DRUG BI 425809 dose 1
- DRUG BI 425809 dose 2
- DRUG BI 425809 dose 3
- DRUG BI 425809 dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2016-07-25 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 2 |
What the finished NCT02832037 record still lists
NCT02832037 is an interventional study that assigns participants to a tested intervention. The registered 509 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02832037 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02832037 about?
NCT02832037 is a clinical study titled "Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia". The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.
What is the current status of trial NCT02832037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 509 participants. The study started on 2016-07-25. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT02832037?
The interventions under investigation include: Placebo (DRUG), BI 425809 dose 1 (DRUG), BI 425809 dose 2 (DRUG), BI 425809 dose 3 (DRUG), BI 425809 dose 4 (DRUG).
Who is sponsoring clinical trial NCT02832037?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02832037's enrollment target sits among peer trials
509 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI